Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,003 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platelets Clear all
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Not yet recruiting Phase 4 Interventional

Endodontic Microsurgery

NCT06776289
View directory record Official record
Conditions
Apical Periodontitis
Interventions
Platelet rich fibrin
Biological
Lead sponsor
Mark Schachman
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Not listed No phase listed Observational

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

NCT03615846
View directory record Official record
Conditions
Platelet Aggregation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

NCT06632418
View directory record Official record
Conditions
Anal Fistula, Complex Perianal Fistula
Interventions
RhPDGF-BB
Drug
Lead sponsor
Alexander Hawkins
Other
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Phase 2 Interventional Results available

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
Ticagrelor, Comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 27, 2026, 7:37 PM EDT
Completed No phase listed Observational Results available

Novel Biomarkers of Thrombotic Risk

NCT02505217
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 27, 2026, 7:37 PM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD

NCT02561520
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
PRP eye drops, PPP eye drops
Biological
Lead sponsor
Ladan Espandar
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00037791
View directory record Official record
Conditions
Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
Interventions
(PN-152,243)/PN-196,444
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
6
States / cities
Berkeley, California • La Jolla, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2006 · Synced Oct 27, 2026, 7:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Platelet-rich Fibrin and Grooving for Sagittal Split Osteotomy

NCT04706182
View directory record Official record
Conditions
Inferior Alveolar Nerve Injury, Nerve Injury, Neurosensory Disorder, Mandibular Nerve Injury
Interventions
Platelet-rich fibrin (PRF), Proximal segment grooving (PSG)
Procedure
Lead sponsor
Jesse Han
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 27, 2026, 7:37 PM EDT
Active, not recruiting Phase 2 Interventional

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Active, not recruiting Not applicable Interventional

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

NCT03537586
View directory record Official record
Conditions
Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia
Interventions
Bivalirudin, Adenosine, Heparin, Pressure-Temperature Sensor Guidewire, Guiding Catheter
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Withdrawn Phase 2 Interventional

Study of Beet Juice for Patients With Sickle Cell Anemia

NCT02162225
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
beet juice (Unbeetable)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated No phase listed Observational

3C Patch® Medicare Claims Study

NCT03997526
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
3C Patch
Device
Lead sponsor
Reapplix
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Natchitoches, Louisiana • Opelousas, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

NCT05523440
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
Interventions
Bevacizumab, Niraparib
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth

NCT02477358
View directory record Official record
Conditions
Pulpal Necrosis
Interventions
Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone, Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Avocado and Postprandial Responses

NCT06818032
View directory record Official record
Conditions
Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions
Negative control, Avocado, Fat and fiber addition
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Withdrawn Phase 4 Interventional

Effectiveness of Aurix Therapy in Venous Leg Ulcers

NCT02940587
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Aurix
Device
Lead sponsor
Cytomedix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Lucanthone, Temozolomide (TMZ), Radiation, Placebo
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans

NCT02154906
View directory record Official record
Conditions
Periodontitis
Interventions
DFDBA, autologous platelet rich fibrin
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 27, 2026, 7:37 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Platelet Rich Fibrin and Autologous Fibrin Glue

NCT03734458
View directory record Official record
Conditions
Gingival Recession
Interventions
Group A - PRF plus AFG with a CAF, Group B - PRF only with a CAF, Group C - CTG with a CAF
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Pentoxifylline Treatment in Acute Pancreatitis (AP)

NCT02487225
View directory record Official record
Conditions
Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

NCT01789814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 27, 2026, 7:37 PM EDT